Immunotherapy

When Cancer Treatment Becomes a Question of the Immune System

A cancer diagnosis often brings urgent questions: Which treatment offers the best chance of controlling the disease? Will the treatment be difficult to tolerate? Is there an option that can work with the body rather than only against the tumor? For many patients, immunotherapy becomes part of this conversation because it uses one of the body’s most complex defense systems: the immune system.

The immune system is designed to recognize what does not belong. It can identify infections, abnormal cells and other threats, then organize a response. Cancer, however, can be difficult for the immune system to detect. Some tumors hide by sending signals that weaken immune activity. Others change over time or create a protective environment around themselves. Immunotherapy is intended to help overcome these barriers, allowing immune cells to recognize cancer cells more effectively and attack them.

For international patients considering treatment abroad, immunotherapy can feel both hopeful and complex. It is not one medication or one simple protocol. It includes several types of treatment, each with specific uses, benefits, limitations and side effects. Some patients receive immunotherapy alone. Others receive it with chemotherapy, targeted therapy, radiation therapy or surgery, depending on the cancer type, stage, biomarkers and overall health.

At a high level, the purpose is clear: immunotherapy aims to improve the immune response against cancer while preserving as much normal function as possible. The right decision requires careful diagnosis, precise staging, molecular and immune biomarker testing when appropriate, and discussion by experienced cancer specialists. This is especially important because immunotherapy can be very effective for some patients, while others may need a different strategy or a combination approach.

What Is Immunotherapy?

Immunotherapy is a group of cancer treatments that help the immune system identify, target and destroy cancer cells. Unlike traditional chemotherapy, which directly attacks rapidly dividing cells, immunotherapy works by influencing immune pathways. It may remove “brakes” that prevent immune cells from attacking cancer, stimulate immune activity, use engineered immune cells, or deliver immune-based substances that support an anti-cancer response.

The most widely used immunotherapies in many cancers are immune checkpoint inhibitors. These medicines target checkpoint pathways, such as PD-1, PD-L1 or CTLA-4, that cancer cells may use to reduce immune attack. By blocking these signals, checkpoint inhibitors can allow immune cells to recognize and respond to the tumor more strongly.

Other forms of immunotherapy include monoclonal antibodies that attach to specific targets on cancer cells, cancer vaccines designed to stimulate immune recognition, immune-modulating medicines, cytokine-based treatments and cellular therapies. In selected blood cancers, cellular therapies may involve collecting a patient’s immune cells, modifying them in a specialized laboratory and returning them to the body so they can recognize cancer cells more effectively.

Immunotherapy is not suitable for every cancer or every patient. Its use depends on the tumor type, disease stage, previous treatments, the patient’s immune status and the presence of certain biomarkers. These biomarkers may include PD-L1 expression, microsatellite instability, mismatch repair deficiency, tumor mutational burden or specific genetic changes. Testing helps the oncology team understand whether the cancer is more likely to respond to immune-based treatment.

In modern cancer care, immunotherapy is often integrated into a broader treatment plan. It may be given before surgery to shrink a tumor, after surgery to reduce the risk of recurrence, together with chemotherapy for metastatic disease, or as maintenance treatment after an initial response. The goal may be cure in certain early-stage settings, long-term control in some advanced cancers, or symptom relief and disease stabilization in others.

Who May Need Immunotherapy?

Patients may be considered for immunotherapy when their cancer type has evidence of benefit from immune-based treatment, when biomarker testing suggests the tumor may respond, or when cancer has progressed after other therapies. It may also be recommended as part of first-line treatment for certain advanced cancers, meaning it is used at the beginning of systemic therapy rather than after chemotherapy has failed.

Common situations that lead to an immunotherapy evaluation include a new diagnosis of advanced or metastatic cancer, recurrence after previous surgery or radiation therapy, cancer that cannot be removed surgically, or a tumor with specific immune or genetic features. Some patients are referred for a second opinion because they want to know whether immunotherapy could be added to, or replace, another planned treatment.

The symptoms that bring a patient to diagnosis vary widely by cancer type. A person with lung cancer may have a persistent cough, shortness of breath, chest discomfort or unexplained weight loss. A patient with melanoma may notice a changing skin lesion. Someone with kidney, bladder, head and neck, stomach, liver, colorectal or blood cancer may present with different signs, ranging from bleeding or fatigue to pain, swelling, appetite changes or abnormal laboratory results. Immunotherapy itself is not chosen based on symptoms alone; it is chosen after the cancer has been accurately diagnosed and characterized.

Diagnosis usually begins with imaging studies and a biopsy. Imaging may include CT, MRI, PET-CT, ultrasound or other tests depending on the suspected cancer. A biopsy allows pathologists to examine tumor tissue under a microscope and, when needed, perform immunohistochemistry, molecular testing or next-generation sequencing. Blood tests may assess organ function, tumor markers, immune-related conditions and suitability for treatment.

Before immunotherapy begins, the oncology team also evaluates the patient’s general health. This includes reviewing autoimmune diseases, organ transplantation history, active infections, lung or liver disease, medications such as corticosteroids or immune suppressants, and previous cancer treatments. Because immunotherapy activates immune pathways, patients with certain immune conditions may need additional caution or a different treatment approach.

Conditions and Cancer Types Immunotherapy Can Address

Immunotherapy is used across a growing range of cancers, although its role differs from one disease to another. It may be a standard treatment in some settings, an option only for tumors with certain biomarkers, or a treatment considered after other therapies. The best approach depends on the individual cancer profile rather than the diagnosis name alone.

Immune checkpoint inhibitors are commonly used in selected patients with melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, certain gastrointestinal cancers, liver cancer, cervical cancer and some breast cancers, among others. In some colorectal and other solid tumors, immunotherapy is especially relevant when the tumor shows mismatch repair deficiency or high microsatellite instability. These features suggest that the tumor may be more visible to the immune system.

In hematologic cancers, immunotherapy may include monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, immune-modulating medicines and cellular therapies for selected leukemias, lymphomas and multiple myeloma. The decision is based on disease subtype, prior treatments, genetic features and the patient’s fitness for therapy.

Immunotherapy may also be used in earlier-stage disease for some cancers. For example, it can be given before surgery, known as neoadjuvant therapy, to reduce tumor burden and allow doctors to evaluate how the cancer responds. It may also be given after surgery, known as adjuvant therapy, to lower the risk of recurrence in patients who have a meaningful risk of microscopic disease remaining.

In advanced cancer, immunotherapy may help shrink tumors, slow progression or create durable disease control in a subset of patients. Some people experience responses that last longer than expected with older treatment approaches. However, not every patient responds, and some cancers develop resistance. This is why treatment planning should combine scientific evidence, biomarker testing and careful clinical judgment.

How Immunotherapy Is Performed: From Preparation to Recovery

Immunotherapy begins with a detailed assessment. Your oncology team reviews your diagnosis, pathology report, imaging studies, previous treatments and overall medical condition. If you are seeking care from another country, it is helpful to share biopsy results, surgical notes, scan images, laboratory results and current medications before travel when possible. This allows the medical team to determine whether additional testing is needed and whether immunotherapy is appropriate.

The preparation phase may include repeat imaging, blood tests, organ function assessment and biomarker testing. Some patients need a new biopsy if previous tissue is insufficient for molecular analysis or if the cancer has changed after earlier treatments. The tumor may be discussed in a multidisciplinary tumor board, where medical oncologists, radiation oncologists, surgeons, radiologists, pathologists, nuclear medicine physicians and other specialists review the case together. This helps align the treatment plan with international, evidence-based protocols while adapting it to the patient’s needs.

Most immune checkpoint inhibitors are given as an intravenous infusion in an outpatient oncology unit. The infusion is administered through a vein, usually over a short period, followed by monitoring. Treatment schedules vary by medicine and cancer type. Some infusions are given every two, three, four or six weeks. Your oncologist will explain the specific schedule, expected number of cycles and how response will be evaluated.

Other immunotherapies may be performed differently. Some monoclonal antibodies are given intravenously or by injection. Cellular therapies involve a more complex process, which may include collecting immune cells from the blood, laboratory preparation, conditioning treatment and infusion back into the patient. These treatments require specialized coordination and monitoring because side effects can be different from standard infusion therapies.

During immunotherapy, technology supports precision at every stage. Advanced imaging helps determine disease stage and measure response. Digital pathology and immunohistochemistry help characterize tumor tissue. Molecular diagnostic platforms can identify genetic and immune biomarkers that influence treatment selection. Modern infusion units support safe administration and monitoring. Electronic medical records and structured oncology protocols help coordinate care among specialists, particularly when treatment is combined with chemotherapy, radiotherapy or surgery.

The procedure itself is usually not painful. Patients sit in an infusion chair while the medication is administered. Nurses monitor vital signs and watch for infusion reactions, which are uncommon but possible. Many patients can return to their hotel or home the same day after routine infusions. Cellular therapies or more intensive regimens may require hospitalization or close observation.

Side effects of immunotherapy are different from those of chemotherapy. Many patients tolerate treatment well, with fatigue, mild rash, itching, joint discomfort, diarrhea or changes in appetite. However, because immunotherapy stimulates immune activity, it can sometimes cause inflammation in healthy organs. These immune-related adverse effects may involve the skin, bowel, liver, lungs, thyroid, adrenal glands, kidneys, nervous system or other organs. Early reporting is essential, because many immune-related side effects can be managed more effectively when recognized promptly.

Response assessment is usually performed with imaging after several treatment cycles. Some tumors shrink quickly; others stabilize first. Occasionally, imaging can appear worse before improving because immune cells enter the tumor, a phenomenon sometimes called pseudoprogression. This is not common, and it must be interpreted carefully by experienced oncologists and radiologists. Treatment decisions are based on symptoms, scan patterns, laboratory findings and overall clinical status.

Recovery during immunotherapy is not a single event, because treatment may continue for months or longer depending on the indication and response. Many patients maintain daily activities, work remotely or travel between treatment cycles, while others need adjustments due to fatigue or immune-related symptoms. The care team provides clear guidance on when to call, which symptoms require urgent evaluation and how follow-up can be coordinated if the patient returns home between cycles.

Why Acting Early Matters

Timing can influence cancer outcomes. When immunotherapy is appropriate, starting treatment at the right point in the disease course may improve the chance of controlling the cancer, avoiding complications and preserving more treatment options. Delays can allow tumors to grow, spread to new organs or cause symptoms that reduce a patient’s ability to tolerate therapy.

Acting early does not mean rushing into treatment without adequate testing. In immunotherapy, careful preparation is part of good timing. A short, focused diagnostic workup may identify biomarkers that change the treatment plan completely. For example, a patient initially expecting chemotherapy alone may be eligible for immunotherapy-based treatment. Another patient may learn that targeted therapy, surgery or radiation should be prioritized first.

Delaying evaluation can also affect performance status, which is a medical measure of how well a patient can carry out daily activities. Many cancer treatments, including immunotherapy combinations, are safer and more effective when patients are still physically strong enough to tolerate them. Untreated cancer can lead to weight loss, pain, breathing problems, organ dysfunction or blood abnormalities that complicate care.

For patients seeking treatment abroad, early coordination is especially important. Medical record review, translation, travel planning, appointment scheduling and insurance or payment documentation may take time. A well-organized second opinion can clarify whether immediate treatment is needed, whether additional tests should be performed before travel, or whether part of the plan can be started locally and continued internationally.

Potential Benefits of Immunotherapy

The potential advantages of immunotherapy depend on cancer type, stage, biomarkers and overall treatment strategy.

Benefit	What It Means for You
Immune-based cancer control	Immunotherapy helps the immune system recognize and attack cancer cells, which may lead to tumor shrinkage or disease stabilization in selected patients.
Durable responses in some cancers	Some patients who respond to immunotherapy experience longer-lasting control than expected with certain older treatment approaches, although responses vary.
Combination flexibility	Immunotherapy can often be combined with chemotherapy, targeted therapy, radiation therapy or surgery when evidence supports a combined approach.
Different side effect profile	Many patients avoid some classic chemotherapy effects, such as hair loss or severe nausea, though immune-related inflammation can occur and must be monitored.
Personalized selection through biomarkers	Testing may help identify patients more likely to benefit and prevent unnecessary treatment when another option is more appropriate.

Recovery and Follow-Up Timeline

Recovery with immunotherapy is usually measured by treatment cycles, symptom monitoring and response assessment rather than by a single procedure date.

Time Period	What Patients Can Expect
Day 1	Most patients receive the infusion in an outpatient setting. The care team monitors for immediate reactions and reviews symptoms that should be reported after leaving.
First Week	Fatigue, mild skin changes, itching, joint discomfort or appetite changes may occur. Many patients continue normal activities, depending on their condition and combination treatments.
First Month	Patients usually continue scheduled cycles and laboratory monitoring. The team watches for immune-related side effects affecting the bowel, liver, lungs, hormones or other organs.
First Few Months	Imaging is typically performed after several cycles to evaluate whether the cancer is shrinking, stable or progressing. Treatment may continue, change or be combined with other modalities.
Longer Term	Follow-up focuses on ongoing disease control, late immune-related effects, quality of life and coordination with local physicians if the patient returns home.

Factors That Influence Outcomes

Immunotherapy outcomes are shaped by many variables. The most important is cancer biology. Some tumors are naturally more responsive to immune-based treatment, especially when they carry immune-recognizable features such as high microsatellite instability, mismatch repair deficiency, high tumor mutational burden or meaningful PD-L1 expression. Other cancers may be less responsive unless immunotherapy is combined with another treatment.

Stage also matters. In earlier-stage cancers, immunotherapy may be used to reduce recurrence risk or improve the effect of surgery. In advanced cancers, the goal may be to shrink tumors, control symptoms and extend meaningful time with good function. The presence of cancer in certain organs, tumor volume and the pace of disease progression can influence how quickly treatment must work and whether combination therapy is preferable.

A patient’s general health plays a central role. People with good organ function, stable nutrition and stronger performance status are often better able to tolerate treatment and manage side effects. Existing autoimmune disease, chronic infections, prior organ transplantation or the need for high-dose immune-suppressing medications may affect safety and treatment selection.

Previous cancer treatments can also influence response. A tumor that has already been exposed to several therapies may behave differently from a newly diagnosed cancer. Prior radiation, surgery, chemotherapy or targeted therapy may change the tumor environment, organ reserve and symptom profile. In some cases, immunotherapy is most effective when used earlier; in others, it is reserved for a later line of treatment.

Side effect recognition is another important factor. Immunotherapy-related inflammation can usually be managed more effectively when patients report symptoms early. Persistent diarrhea, shortness of breath, severe fatigue, yellowing of the skin or eyes, new headaches, vision changes, chest pain, confusion, decreased urination or severe rash should not be ignored. Patients should not self-treat these symptoms without contacting their oncology team, because immune-related side effects require specific evaluation and sometimes corticosteroids or other immune-modulating treatment.

Finally, outcomes improve when care is coordinated. Immunotherapy decisions often require input from medical oncology, radiology, pathology, surgery, radiation oncology and organ-specific specialists such as pulmonologists, gastroenterologists or endocrinologists. This collaboration helps ensure that treatment response and side effects are interpreted correctly and that adjustments are made at the right time.

Why International Patients Choose Acibadem for Immunotherapy

For patients traveling for cancer care, the medical decision is only one part of the journey. They also need confidence that their diagnosis will be reviewed thoroughly, that treatment recommendations will reflect current evidence, and that communication will be clear across languages, cultures and health systems. Acibadem provides immunotherapy within a structured oncology environment designed for complex international care.

Acibadem hospitals are JCI-accredited, reflecting internationally recognized standards for patient safety, quality processes and clinical governance. For cancer patients, this matters because immunotherapy requires careful medication handling, standardized infusion protocols, rapid response to adverse effects and coordination between multiple departments. The goal is not only to provide treatment, but to deliver it within a system that anticipates risk and monitors each step.

Multidisciplinary evaluation is central to cancer care at Acibadem. Patient cases may be reviewed by tumor boards or specialist boards where medical oncologists, surgical oncologists, radiation oncologists, radiologists, nuclear medicine specialists, pathologists and other physicians discuss diagnosis and treatment options together. This is particularly valuable for immunotherapy, where decisions often depend on stage, biomarkers, imaging interpretation, previous treatments and the possibility of combining therapies.

Diagnostic capability is also important. Immunotherapy planning may require high-quality imaging, pathology review, immunohistochemical staining and molecular analysis. These tools help confirm the cancer subtype, evaluate disease extent and identify biomarkers that may influence treatment. When international patients arrive with records from another country, Acibadem physicians can review existing materials and recommend additional tests only when they are clinically necessary.

Treatment plans are personalized rather than based on a single protocol for all patients. A person with early-stage disease being considered for surgery has different needs from someone with metastatic cancer and prior chemotherapy. A patient with autoimmune disease requires different risk assessment from a patient without immune complications. Acibadem physicians consider cancer biology, general health, treatment goals, travel logistics and the patient’s preferences when developing a plan.

Advanced technology supports both diagnosis and treatment monitoring. Imaging systems help define disease burden and evaluate response. Pathology and molecular diagnostic platforms support biomarker-guided decisions. Modern radiotherapy and surgical capabilities allow immunotherapy to be integrated with local treatments when appropriate. Infusion services are designed for safe administration, observation and patient education, with attention to the specific side effects associated with immune-based medicines.

International patient services are an important part of the experience. Acibadem International assists patients from abroad with appointment coordination, medical record review, interpretation, travel-related organization and communication with hospital departments. Support is available in more than 20 languages, helping patients and families understand the treatment plan, consent process, medication schedule and follow-up requirements. For a patient receiving immunotherapy, this clarity can be essential because treatment may extend over multiple cycles and may require coordination with physicians in the patient’s home country.

Experienced physicians are especially important in immunotherapy because the treatment can produce patterns that differ from traditional chemotherapy. Tumors may respond gradually. Side effects may resemble common conditions, such as colitis, pneumonia, thyroid disease or hepatitis, but require immune-specific management. Oncologists who regularly use these therapies are better prepared to distinguish expected symptoms from warning signs and to adjust treatment when needed.

For many international patients, Acibadem also offers the possibility of a structured second opinion. This can be valuable if a patient has been told there are limited options, if biomarker testing has not been completed, if a combination treatment is being considered, or if there is uncertainty about whether immunotherapy is appropriate. A second opinion may confirm the current plan, suggest additional testing or identify an alternative treatment sequence.

Moving Forward With an Informed Immunotherapy Plan

Immunotherapy has changed the treatment landscape for many cancers, but it is not a universal solution. Its value depends on choosing the right patient, the right timing and the right combination of care. For some people, it may offer meaningful disease control with a manageable treatment schedule. For others, a different approach may be safer or more effective. The most important step is a careful evaluation by an oncology team experienced in interpreting cancer biology, biomarkers and treatment history.

If you are considering immunotherapy, preparing your medical records can make the consultation more productive. Useful documents include pathology reports, biopsy slides or blocks if available, imaging reports and scan files, previous treatment summaries, surgery records, radiation details, laboratory results, medication lists and information about autoimmune or chronic conditions. These materials help the oncology team determine whether immunotherapy is appropriate and what additional tests may be needed.

At Acibadem, international patients can request a consultation or second opinion to better understand whether immunotherapy should be part of their cancer treatment plan. The aim is to provide a clear, evidence-based recommendation that reflects both the science of the disease and the individual circumstances of the patient.

This information is general and is not a substitute for professional medical advice. Diagnosis and treatment decisions should always be made with a qualified physician who can evaluate your individual medical condition.